fda approval of tirzepatide for weight loss is approved Semaglutide vs. Tirzepatide: Which Treatment Right You? Choosing between FDA approves new version of

What they found: In normal obese mice: AOD-9604 reduced body fat by 21 % vs placebo, hGH by 24 % The AOD-9604 effect was fully dependent on the 3-adrenergic receptor , in knock-out mice no effect The hGH effect was partly independent of 3-AR , in knock-out mice there was still ~10 % fat reduction AOD-9604 did not raise IGF-1 (control level), whereas hGH raised IGF-1 by 80 % No changes in growth, organ weights (except adipose tissue), fasting insulin Why it matters: The study provided the mechanistic basis for AOD-9604 and confirmed the key business hypothesis: it is possible to separate the lipolytic effect of GH from its growth effect

Brain Sciences , 7

Injectable formulations like Ozempic, Trulicity, and Mounjaro are widely prescribed, with user-friendly pen devices enhancing patient compliance

Oxidative stress is one of the culprits responsible for the development and progression of diabetic neuropathy

BPC-157 may also upregulate the expression of early growth response gene-1 (EGR-1), which is a growth factor with potential benefits for the nervous system, having been suggested to aid in early extracellular matrix (collagen) formation [5]

Tirzepatide creates a potential path to corticosteroid reduction through two mechanisms